April 03, 2017

Evolva announces long-term commercial agreement with Cargill

EverSweetTM next-generation stevia ingredient on track for 2018 launch

Evolva (SIX: EVE) announced today that it has entered a major collaboration agreement with Cargill for the production and commercialisation of EverSweetTM, the next-generation stevia sweetener.This product is on track for a 2018 launch, securing its first-mover advantage.
PDF Download - English Version
PDF Download - German Version



 

Evolva (SIX: EVE) announced today that it has entered a major collaboration agreement with Cargill for the production and commercialisation of EverSweetTM, the next-generation stevia sweetener. This product is on track for a 2018 launch, securing its first-mover advantage. - See more at: http://www.evolva.com/press-release/evolva-announces-long-term-commercial-agreement-with-cargill/#sthash.nb6PmIJw.dpuf
Evolva (SIX: EVE) announced today that it has entered a major collaboration agreement with Cargill for the production and commercialisation of EverSweetTM, the next-generation stevia sweetener. This product is on track for a 2018 launch, securing its first-mover advantage. - See more at: http://www.evolva.com/press-release/evolva-announces-long-term-commercial-agreement-with-cargill/#sthash.nb6PmIJw.dpuf
Evolva (SIX: EVE) announced today that it has entered a major collaboration agreement with Cargill for the production and commercialisation of EverSweetTM, the next-generation stevia sweetener. This product is on track for a 2018 launch, securing its first-mover advantage. - See more at: http://www.evolva.com/press-release/evolva-announces-long-term-commercial-agreement-with-cargill/#sthash.XkBKDeqO.dpuf

read more »

March 30, 2017

Symetis and Boston Scientific reach USD 435 million purchase agreement

Symetis, a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions, today announced that it has agreed to be acquired by Boston Scientific for $435 million in an all cash, up-front payment.
PDF Download

read more »

March 09, 2017

Evolva achieves second milestone in fragrance & flavour alliance with Takasago

Evolva (SIX: EVE) today announces reaching the second technical milestone under the multi-year R&D alliance with Takasago. This achievement brings the project closer to the launch of the target ingredients and prompts a total milestone payment of USD 1 million to Evolva as well as the continuation of the collaboration into the next phases.
PDF Download - English version
PDF Download - German version
 

read more »

February 20, 2017

New Data Demonstrate that Synaffix ADCs Significantly Expand the Therapeutic Index vs Cysteine-Engineered ADCs

Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology, today announced a new set of head-to-head data, that demonstrates the potential of its technology to significantly expand the therapeutic index vs cysteine-engineered ADCs.
PDF Download

read more »

January 17, 2017

Bird Rock Bio Receives Approval to Start First in Human Clinical Trial for Namacizumab, Enters Into Agreement with GE Healthcare for Process Development and Scale-up to Provide Clinical Phase 2 cGMP Material

and enters into a Collaboration and Option Agreement with Janssen Pharmaceuticals, Inc.

Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, announced today that it has received approval for the initiation of a two-part Phase 1 clinical trial for namacizumab, a novel therapeutic antibody to the cannabinoid 1 receptor (CB1). In addition, Bird Rock Bio has entered into an agreement with GE Healthcare for process development, formulation, and manufacture of namacizumab in preparation for Phase 2 studies. Furthermore, the Phase 1 trial, process development, and Phase 2 preparation will be funded under a collaboration and option agreement with Janssen Pharmaceuticals, Inc.
PDF Download

read more »

December 05, 2016

Novimmune grants Genentech an exclusive option to license NI-0101, its anti-TLR4 monoclonal antibody for the treatment of rheumatoid arthritis

Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs, today announced that it has entered into an exclusive option and license agreement with Genentech, a member of the Roche Group, for the development and commercialization of NI-0101, an anti-TLR4 (Toll-like receptor 4) monoclonal antibody, for the potential treatment of rheumatoid arthritis and other autoimmune diseases.
PDF Download

read more »

October 27, 2016

Bird Rock Bio Submits Clinical Trial Authorization for the First in Human Clinical Trial for Namacizumab

Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, announced that today it has requested approval for the initiation of a two-part Phase 1 clinical trial for namacizumab, a novel therapeutic antibody to the cannabinoid 1 receptor (CB1).  The trial is anticipated to provide important safety, tolerability and biomarker efficacy data for namacizumab to support differentiated clinical potential in fibrotic and metabolic disease.  As a first-in-class and only-in-class negative allosteric modulating antibody (NAMA) that stabilizes the inactive conformation of CB1, namacizumab has the potential to build on the significant historic mechanistic and clinical data on the modulation of CB1 in disease.
PDF Download

read more »

October 27, 2016

ERS Genomics and Evolva Sign License Agreement on CRISPR-Cas9 Genome Editing Patents for Industrial Applications

ERS Genomics Ltd and Evolva (SIX:EVE), a leader in fermentation-based approaches to specialty chemicals, announced today a non-exclusive license agreement which provides Evolva with worldwide access to ERS’ CRISPR-Cas9 genome editing intellectual property for use in engineering yeast and fungi for production of ingredients for human and animal health, wellness and nutrition, food and beverages, and other industrial applications. ERS Genomics holds rights to the foundational CRISPR-Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology.
PDF Download - English Version
PDF Download - German Version

read more »

October 20, 2016

Synaffix Enters into a Commercial License Agreement with ADC Therapeutics

Synaffix BV announced today it has entered into a Commercial License Agreement with ADC Therapeutics for its proprietary GlycoConnect™ and HydraSpace™ site-specific antibody-drug conjugate technologies.
PDF Download

read more »

August 10, 2016

Evolva’s collaboration with US Navy to focus on resveratrol-based composites

Testing underway of materials fabricated from special formulation of Evolva’s resveratrol

Evolva’s (SIX: EVE) collaboration with the US Navy (NAVAIR research facility, China Lake, California) to develop novel composite materials is to focus on the development of a new class of structural composite materials engineered from a polymer resin matrix fabricated from a specified formulation of Evolva’s resveratrol. Evolva has produced and delivered this specified formulation, and will continue to work with the Navy to advance this new class of composites.
PDF Download - English Version
PDF Download - German Version

read more »

July 28, 2016

Cornelius and Evolva bring new fermented resveratrol to market

Evolva (SIX: EVE) announces teaming up with Cornelius Group, an independent European distributor of high quality, innovative ingredients, for the marketing of resveratrol in certain European markets. Evolva’s resveratrol is produced via an innovative fermentation process using yeast.
PDF Download - English Version
PDF Download - German Version

read more »

July 25, 2016

Evolva’s nootkatone enters NIH-sponsored studies to assess its effectiveness against mosquitoes that transmit Zika virus

Evolva (SIX: EVE) announces that the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will sponsor studies to test Evolva’s nootkatone against mosquitoes infected with Zika virus. The study will evaluate nootkatone in multiple formulations against wild type and insecticide-resistant mosquitoes that carry the virus.
PDF Download - English Version
PDF Download - German Version

read more »

July 20, 2016

Synaffix Achieves Significantly Improved Therapeutic Index Compared to Both FDA-Approved ADCs and expands its Scientific Advisory Board

Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced the completion of a new set of preclinical studies that further supports the potential for its technology to enable safer and more effective targeted cancer therapeutics.  The data obtained in these studies capture the outcomes from its latest R&D efforts demonstrating that Synaffix platform technologies, GlycoConnect™ and HydraSpace™, generate ADCs with significantly improved therapeutic index when compared directly to Kadcyla® and Adcetris®, the two FDA-approved ADCs for the treatment of Her2-positive breast cancer and multiple lymphoma indications, respectively.
PDF Download

read more »

May 26, 2016

Evolva granted pivotal patent for commercial production of best-tasting fermentation-derived steviol glycosides

Enabling patent key to the commercial expansion of and broader access to stevia sweeteners

Evolva (SIX: EVE) announces that the European Patent Office has granted the Company patent number 2742142, intellectual property pivotal to the commercial expansion of and broader access to the best-tasting stevia-sweeteners made possible through the introduction of yeast fermentation-derived steviol glycosides.
PDF Download - English Version
PDF Download - German Version

read more »

May 17, 2016

Novimmune doubles down in HLH; second $31M round this year

Novimmune SA closed a CHF30 million (US$31 million) funding round, taking the total cash it has raised this year to CHF60 million and its lifetime total to more than CHF300 million.
PDF Download

read more »

April 11, 2016

Evolva to co-develop next-generation materials with US Navy

Applications include fire resistant coatings and structural materials for use in aircraft, waterborne craft, fabrics and construction

Evolva (SIX: EVE) announced that it has completed a Limited Purpose Cooperative Research and Development Agreement (CRADA) to support the joint development of novel advanced materials with the US Navy. The focus of the efforts supported by this CRADA relate to the development, validation and potential commercialisation of new lightweight, fire-resistant composite materials to save lives and reduce harm from fire.
PDF Download- English Version
PDF Download - German Version
 

read more »

April 05, 2016

Evolva gains exclusive license to develop and commercialise nootkatone globally for pest control

Evolva also signs broader nootkatone collaboration agreement with CDC

Evolva (SIX: EVE) announces that it has just signed a license agreement with the US Centers for Disease Control and Prevention (CDC) that grants Evolva the exclusive worldwide patent rights to develop and commercialise nootkatone for the control of a wide range of disease and virus vectors such as ticks, mosquitoes, fleas, flies, lice, bed bugs, and other biting insects.
PDF Download - English Version
PDF Download - German Version
 

read more »

March 11, 2016

Jean-Philippe Tripet speaks about the start-up scene in Switzerland

While Switzerland is very proud of its leading position in innovation ranking, a comparison with peer countries shows that we are poor in commercialising this excellent science (Gap 1).  Jean-Philippe Tripet CFA, to discuss Aravis' research showing that Switzerland invests 3 times less than Sweden and 6 times less than Israel in start-ups. With 200-300 start-ups per year, there is no deal flow issue. However, there is clear evidence that we significantly lack investment in new venture and small companies (Gap 2).
PDF Download

read more »

March 02, 2016

Evolva achieves milestones in flavour & fragrance alliance with Takasago

Evolva (SIX: EVE) today announces reaching the first technical milestones under the multi-year R&D alliance with Takasago. This achievement, taking place three months ahead of schedule, prompts a total milestone payment of CHF 1 million to Evolva.
PDF Download - English Version
PDF Download - German Version
 

read more »

February 17, 2016

Switzerland needs much more Venture investments

Unausgeschöpftes Potenzial -Obwohl die Schweiz eine der innovativsten Nationen weltweit ist, gibt es bei der Kommerzialisierung dieser Innovationen noch ziemlich viel Potenzial.

Obwohl die Schweiz eine der innovativsten Nationen weltweit ist, gibt es bei der Kommerzialisierung dieser Innovationen noch ziemlich viel Potenzial. Die Schweizer Pensionskassen investieren wenig in Start-ups. Dabei wäre Potenzial vorhanden.
PDF Download
 

read more »

February 16, 2016

Synaffix Announces Its Newly Constructed High Potency Lab Is Now Fully Operational

Synaffix BV, a biotechnology company exclusively focused on the development of an industry-leading antibody-drug  onjugate (ADC) technology, today announced that its newly constructed high potency
laboratory is now fully operational.
PDF Download

read more »

February 09, 2016

Bird Rock Bio Announces Corporate Name Change from RuiYi, Inc.

Change reflects evolution from discovery research to global clinical development company focused on developing innovative immuno-inflammatory regulators

Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, today announced its corporate name change from RuiYi, Inc. to Bird Rock Bio.
PDF Download

read more »

January 19, 2016

Aravis Biotech II: another exit

ACORDA ANNOUNCES A RECOMMENDED CASH TENDER OFFER FOR ALL SHARES, ADSs AND OTHER EQUITY INSTRUMENTS IN BIOTIE

Acorda Therapeutics, Inc. ("Acorda") and Biotie Therapies Corp. ("Biotie" or the "Company") have today entered into a combination agreement ("Combination Agreement") whereby Acorda, either directly or through a wholly-owned subsidiary (jointly the "Offeror"), will make a public tender offer in Finland and in the United States to purchase all of the issued and outstanding shares, American Depositary Shares ("ADSs"), stock options, share units and warrants in Biotie that are not owned by Biotie or any of its subsidiaries (the "Tender Offer").
PDF Download

read more »

January 19, 2016

Evolva clarifies key points in recent bank analyst note

Evolva (SIX: EVE) provides a clarification to Bank Vontobel’s analyst note of yesterday.

As previously reported, Evolva is in active discussions with Cargill regarding the optimal way to commercialise EverSweet™ and share the returns between Evolva and Cargill. These negotiations are being held in a positive and constructive manner.
PDF Download

read more »

January 11, 2016

Novimmune Completes CHF30 Million ($29.8 Million) Funding Round with Existing Shareholders

Broad Participation from Shareholder Base to Invest in Developing the Drug Pipeline, Including NI-0501 for Hemophagocytic Lymphohistiocytosis (HLH)

Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory and rare diseases, immune-related disorders and cancer, today announced it has completed a CHF30 million ($29.8 million) funding round.
PDF Download

read more »

January 07, 2016

Synaffix Appoints World Leading Experts to Scientific Advisory Board and Recruits Chairman to Board of Directors

Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology, today announced the appointment of a panel of industry experts to its inaugural scientific advisory board (SAB). Concurrent with the launch of the SAB, Synaffix has appointed Dr. Konstantinos Efthymiopoulos as the independent chairman of its Board of Directors.
PDF Download

read more »

January 05, 2016

ARAVIS terminates its energy activities

Aravis SA shut down its energy division as of 31 December 2015

Over the past six years, Aravis’ energy team has successfully invested in renewable energy assets across Europe. Investors in Aravis Energy I LP, a FINMA-regulated Swiss fund launched in 2009 and liquidated in 2015, received more than double of their commitments. The high return was attributable to the fund’s well differentiated build-and-sell strategy as well as the team’s ability to identify and exploit special situations, which enabled the fund to keep hold periods short and associated risks low. Besides Aravis Energy I LP, Aravis’ energy division has been accountable for a number of successful investments executed under advisory mandates.
PDF Download

read more »

December 23, 2015

Evolva achieves stevia milestone

Evolva (SIX: EVE) announces that it has achieved another technical milestone in its partnership with Cargill, Inc. to commercialise EverSweet™, the next-generation, zero-calorie stevia sweetener. Reaching this milestone triggers the payment of USD 0.5 million by Cargill to Evolva.
PDF Download - English Version
PDF Download - German Version
 

 

read more »

December 07, 2015

Evolva launches valencene

Evolva (SIX: EVE) announces the launch of valencene, a highly prized orange flavour and fragrance (F&F) ingredient. As an alternative to extracting it from the skin of oranges, Evolva’s process allows valencene to be made in large amounts in a highly reproducible, contaminant free, sustainable and affordable manner. Evolva has developed a cost efficient manufacturing process at large production scale for valencene and we will start shipping initial commercial samples to prospective clients in January.
PDF Download - English Version
PDF Download - German Version

read more »

December 01, 2015

Novimmune’s Experimental Drug Selected for Oral Presentation at 2015 Annual Meeting of the American Society of Hematology (ASH)

Late-Breaking Abstract on NI-0501 for Treatment of Hemophagocytic Lymphohistiocytosis (HLH) One of Only Eight Accepted

Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory and rare diseases, immune-related disorders and cancer, today announced that the abstract on Hemophagocytic Lymphohistiocytosis (HLH) will be presented in the Late-Breaking Abstracts oral session at the 2015 Annual Meeting of the American Society of Hematology in Orlando, Florida on Tuesday, December 8.
PDF Download

read more »

November 02, 2015

Evolva successfully completes Roquette collaboration, triggering a fourth milestone payment

Evolva (SIX: EVE) today announces the successful completion of the collaboration with Roquette Frères (Roquette), which started in January 2012. The project focussed on an ingredient with important applications in food products.
PDF Download - English Version
PDF Downoad - German Version

read more »

October 13, 2015

PREQIN confirms top performance of ARAVIS’ energy fund

Over the past six years, Aravis Energy I LP has successfully invested in renewable energy assets across Europe. Following the last two exits earlier this year, the fund is now being liquidated, remarkably five years ahead of the contractual lifetime. Investors received more than double of their commitments, yielding an IRR of 448%. The high return is attributable to the fund’s well differentiated build-and-sell strategy as well as the team’s ability to identify and exploit special situations, which enabled the fund to keep hold periods short and associated risks low.
PDF Download

read more »

October 01, 2015

Cargill unveils zero calorie, great tasting next-generation stevia sweetener

Cargill issued a press release today announcing that next week in Las Vegas at the SupplySide West conference it will unveil EverSweetTM, the great tasting, next-generation stevia sweetener co-developed with Evolva.
PDF Download - English Version
PDF Download - German Version

read more »

September 20, 2015

MerLion’s Finafloxacin Shown to be More Efficacious than Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections

MerLion Pharmaceuticals (“MerLion”) today presented detailed data from its Phase 2 study in patients hospitalized with complicated urinary tract infections (cUTI) and pyelonephritis showing that a five day course of its novel antibacterial, finafloxacin, was more effective than treatment with the current standard of care (ciprofloxacin).
PDF Download

read more »

September 15, 2015

MerLion to Present Detailed Phase 2 Data on Efficacy of Finafloxacin in Complicated Urinary Tract Infections at International Congress of Chemotherapy and Infection (ICC)

MerLion Pharmaceuticals (“MerLion”), a biopharmaceutical company based in Singapore and Berlin, today announced that detailed data from the Phase 2 clinical trial on the efficacy of finafloxacin will be presented at the joint Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Society of Chemotherapy (ISC) International Congress of Chemotherapy and Infection (ICC), taking place on September 17-21 in San Diego.
PDF Download

read more »

September 03, 2015

Evolva announces details of rights offering

Evolva Holding SA (SIX: EVE, “Evolva” or the “Company”) today publishes the terms of the planned rights offering. As previously announced on 26 August 2015, Evolva plans to raise new equity capital to support the stevia launch and other growth initiatives. The rights offering relates to 62,412,477 new registered shares with a nominal value of CHF 0.20 each.
PDF Download - English Version
PDF Download - German Version
 

read more »

September 01, 2015

Symetis announces intention to float on SIX Swiss Exchange

Symetis is a leading Swiss medical technology company active in the fast growing TAVI (transcatheter aortic valve implantation) market • Offering of primary shares to raise approximately CHF 80 million, excluding 15% over-allotment option

Symetis SA, a leading Swiss medical technology company, focused on transcatheter aortic valve implantation (TAVI), announced today its intention to float its shares and list on SIX Swiss Exchange in 2015. Proceeds from the initial public offering (IPO) will enable the company to accelerate and expand its commercial activities in the EU, strengthen its proprietary product pipeline and technology platform, as well as expand its activity in Asia and the United States.
Download PDF - Press Release  English Version
Download PDF - Press Release German Version
Download PDF - Press Release French Version
 

read more »

August 21, 2015

Evolva launches nootkatone for F&F

US EPA letter facilitates potential approval as tick and insect repellent

Evolva (SIX: EVE) announces the launch of nootkatone, a highly prized citrus flavour and fragrance (F&F) ingredient. By brewing nootkatone from sugar, rather than extracting it from the skin of grapefruits, Evolva’s process allows nootkatone to be made in large amounts in a highly reproducible, contaminant free, sustainable and affordable manner. Evolva has now begun selling nootkatone as a F&F ingredient to food, beverage, personal care, and home care product producers around the world.
PDF Download - English Version
PDF Download - German Version

read more »

July 21, 2015

Biotie announces start of tozadenant Phase 3 Study in Parkinson's disease

Biotie (Nasdaq Helsinki BTH1V; NASDAQ: BITI) announces the start of the Phase 3 clinical study of tozadenant, an investigational adenosine A2a receptor antagonist, in patients with Parkinson's disease (PD) experiencing levodopa related end-of-dose "wearing-off".
PDF Download

read more »

June 11, 2015

Biotie Announces Completion of Pricing of U.S. Public Offering of ADSs and Conversion of Convertible Notes

Biotie Therapies Corp. ("Biotie" or the "Company"), a specialized drug development company focused on products for neurodegenerative and psychiatric disorders, has completed the pricing of its U.S. public offering of 3,761,418 ADSs at a price to the public of $14.888 per ADS for gross proceeds of $55,999,991.18 (€49,649,783.83 at the fixed ECB exchange rate of $1.1279 per euro as at June 10, 2015). The share to ADS ratio is 80 to one, and the ADSs will represent 300,913,440 newly issued shares in the Company with a subscription price of €0.165 (rounded figure) per new share (at the above mentioned fixed exchange rate).
PDF Download

read more »

June 08, 2015

Biotie Increases Proposed U.S. Public Offering of ADSs

Biotie Therapies Corp. ("Biotie" or the "Company"), a specialized drug development company focused on products for neurodegenerative and psychiatric disorders, has decided to increase its proposed U.S. public offering from $50 million to $56 million American Depositary Shares ("ADSs") representing its shares.
PDF Download

read more »

June 04, 2015

Biotie Commences Proposed U.S. Public Offering of ADSs

Biotie Therapies Oyj, a specialized drug development company focused on products for neurodegenerative and psychiatric disorders, has today commenced the marketing of a proposed U.S. public offering of $50 million American Depositary Shares ("ADSs") representing its shares, based on the authorization granted by the Annual General Meeting of shareholders on May 26, 2015.
PDF Download

read more »

May 21, 2015

Chinese Consortium Enters into Agreement to Acquire Ambrx

A consortium (the “Consortium”) consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright Limited’s healthcare fund (“CEL Healthcare Fund”), and WuXi PharmaTech announced today that the Consortium has signed a merger agreement pursuant to which the Consortium will acquire Ambrx Inc. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions. Other details of the transaction were not disclosed.
PDF Download

read more »

May 20, 2015

Evolva CEO exercises options, increases his shareholding in Evolva

Evolva (SIX: EVE) today announces that Neil Goldsmith, CEO of Evolva, has exercised options that he held to acquire 3.8 million new Evolva shares, simultaneously selling 2.2 million of them to cover the acquisition costs and taxes related to the option transaction, leaving him with an additional 1.6 million shares.
PDF Download - English Version
PDF Download - German Version

read more »

May 14, 2015

¨Biotie Has Filed Registration Statement for U.S. Public Offering

In accordance with its previously announced plans, Biotie Therapies Corp. ("Biotie") has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to its proposed U.S. public offering of American Depositary Shares, representing Biotie's ordinary shares ("ADSs"). The number of ADSs to be offered and the price range for the offering have not yet been determined. Biotie has made an initial submission to list its ADSs on the NASDAQ Global Market under the ticker symbol "BITI".
PDF Download

read more »

May 11, 2015

Cargill and Evolva Start Engineering Work on Production Facility for Next-Gen Stevia Sweeteners

Evolva informs Cargill of intent to exercise 45% option

Evolva and Cargill have agreed to begin the engineering phase for converting an existing Cargill manufacturing facility to produce next-generation stevia sweeteners (steviol glycosides). The ingredients are expected to be commercially available in 2016.
PDF Download - English Version
PDF Download - German Version

read more »

April 23, 2015

ARAVIS sells two German wind farms

Aravis Energy I LP, a Swiss renewable energy fund advised by Aravis, successfully completed the sale of two companies comprising two German wind farms to a Swiss power supplier. “We have once again been able to successfully exit investments, which further strengthens our track record of delivering returns to investors. This proves our agility and high-quality skills of implementing attractive investment projects in accordance with the investment strategy.’’, commented Oliver Thalmann, Managing Partner of Aravis. The German wind farms are located in Rhineland-Palatinate respectively Brandenburg. Both wind farms benefit from attractive long-term feed-in tariffs. These tariffs do not correlate with other commodity market prices such as those for oil and gas, thereby offering an efficient diversification effect to investors.
PDF Download

read more »

April 23, 2015

Biotie provides update on tozadenant Phase 3 program

Biotie has further refined its plans for the design and conduct of Phase 3 trials in Parkinson's disease (PD) patients experiencing levodopa related end-of-dose 'wearing-off' (motor fluctuations). The phase 3 program will consist of a double- blind trial with an open-label extension and, providing this demonstrates safety and efficacy, will be followed by a separate open-label trial to generate further clinical safety data.
PDF Download

read more »

April 23, 2015

Evolva completes transfer of EV-035 to Emergent BioSolutions, triggering a USD 4 million payment

Evolva (SIX: EVE) today announces the US government’s approval of the transfer (“novation”) of the GC-072 contract to Emergent BioSolutions Inc. (NYSE: EBS). This triggers a payment of USD 4 million to Evolva, following an initial upfront payment of USD 1.5 million in December 2014. This does not change the revenue guidance for 2015.
PDF Download - English Version
PDF Download - German Version

read more »

April 15, 2015

Bilan, 15.04.2015 - L'etoile montante des medtech suisses

SYMETIS DOIT MAINTENANT CHANGER D'ECHELLE. CELA PASSE PAR SON RACHAT OU PAR UNE INTRODUCTION EN BOURSE

Apres une vague d'acquisitions , le  secteur  abesoin  de nouvelles  locomotives helvetiques.   En pleine  croissance, l'entreprise vaudoise  Symetis est une bonne  candidate.
PDF Download

read more »

March 31, 2015

Biotie announces start of patient enrolment into Phase 2a clinical study with BTT1023 in primary sclerosing cholangitis

Biotie Therapies Corp ("Biotie") announces the start of patient enrolment into the Phase 2a clinical study evaluating BTT1023, Biotie's fully human monoclonal antibody targeting Vascular Adhesion Protein-1, in primary sclerosing cholangitis (PSC). PSC is a progressive immune mediated biliary disease characterised by bile duct inflammation and fibrosis, and accompanying hepatic fibrosis, that frequently results in the need for liver transplantation. The study is being funded through the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership*.
PDF Download

read more »

March 26, 2015

Evolva and Valent BioSciences to co-develop agricultural bioactives

Evolva (SIX: EVE) and Valent BioSciences Corporation (VBC), a subsidiary of Tokyo-based Sumitomo Chemical Company, have signed an exclusive agreement to co-develop and commercialise a class of high-value active ingredients for use as next-generation agricultural bioactives. For competitive reasons, the ingredients are not being identified at this time.
PDF Download - English Version
PDF Download - German Version

read more »

March 10, 2015

Mallinckrodt to acquire Ikaria in $2.3 bln deal. Early investor Aravis Exits along side with PE Madison Dearborn

Ikaria is being sold for $2.3 billion to global biopharmaceutical company Mallinckrodt. In 2005 Aravis, through its Biotech venture I fund, had joined the initial Series A financing of Ikaria Inc, together with 5am, Venrock and Arch. Over time through various innovative M&A and financing steps the company has grown into a highly profitable specialty company. The purchase by Mallinckrodt follows last years’ partial sale to Madison Dearborne and the listing of Ikaria’s spin out Bellorophon (BLPH; NASDAQ).
PDF Download

read more »

March 10, 2015

Ajinomoto project moves into the next phase triggering a milestone payment to Evolva

Evolva (SIX: EVE) today announces that Ajinomoto Co. Inc., Japan, has confirmed that Evolva has completed the first R&D phase in their collaboration and that the collaboration is moving into its next phase. The ultimate objective of the collaboration is the joint development of novel fermentation production routes for a natural functional ingredient for application in Personal Care. Evolva has developed an innovative process that allows Ajinomoto to manufacture the target ingredient. In recognition of the progress and several new findings, Ajinomoto will make a milestone payment to Evolva.
PDF Download - English Version
PDF Download - German Version

read more »

February 27, 2015

Biotie Financial Statement Release 2014

Biotie Financial Statement Release 2014 - This is a summary of the financial statement report 2014 published today.

Company Highlights
October - December 2014 :

- Preparations to advance tozadenant into Phase 3 development in Parkinson's disease as part of Biotie's proprietary portfolio continued during the quarter. The Phase 3 program is expected to start recruiting patients in the middle of 2015.

- Biotie advanced SYN120, a 5-HT6 / 5-HT2a antagonist, into Phase 2 development. The SYNAPSE study, a Phase 2a clinical study in patients with Parkinson's disease dementia, started in December 2014. The study is largely funded by The Michael J. Fox Foundation (MJFF).

- Biotie's partner H. Lundbeck A/S (Lundbeck) continued the rollout of Selincro in Europe and it has now been introduced in 26 European markets. Favorable reimbursement decisions have been issued in a number of European markets, including France, Spain and the United Kingdom, where NICE issued its final positive guidance in November 2014.

- Annual impairment review of intangible assets and goodwill resulted in a non-cash impairment charge of EUR 27.6 million in respect of nepicastat and SYN120.

- Biotie's revenue in Q4 2014 was EUR 1.9 million (EUR 5.8 million) and the financial result was a net loss of EUR 32.4 million (net profit of EUR 1.7 million).

- Biotie ended 2014 with liquid assets of EUR 32.4 million (EUR 35.9 million, 30 September 2014). Operating cash flow for the full year was a net outflow of EUR 14.1 million (net inflow of EUR 10.6 million).

PDF Download

read more »

February 16, 2015

Aravis to present at the Innovationsforum Energie in Zurich on the 20th of March

Aravis has been invited to speak at the 5th Innovationsforum Energie in Zurich on 20th March 2015. Besides sharing practical insights from Aravis experiences in Investment in the energy sector, the following pertinent issues will be addressed:
- Analysing the market to ascertain what is the appetite of investors for European Infrastructure;
- How do Financial Investors view investments in the Energy sector today;
- What are some possible collaborations models between utilities and financial investors when financing energy infrastructure projects?

read more »

February 13, 2015

Bellerophon Therapeutics Announces Pricing of Its Initial Public Offering

Bellerophon Therapeutics announced today the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $12.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Bellerophon. In addition, Bellerophon has granted the underwriters an option to purchase up to 750,000 additional shares of common stock at the public offering price, less the underwriting discount.  Bellerophon's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the ticker symbol "BLPH" on February 13, 2015.  The offering is expected to close on February 19, 2015, subject to customary closing conditions.
PDF Download

read more »

February 12, 2015

MerLion announces FDA approval of finafloxacin otic suspension - First novel drug from a Singapore company to achieve FDA approval

MerLion Pharmaceuticals (MerLion), a biopharmaceutical company headquartered in Singapore with clinical development operations in Berlin, Germany, today announced that an otic suspension of finafloxacin has been approved by the FDA to treat acute otitis externa, commonly known as “swimmer’s ear”, caused by Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin was licensed by MerLion to a major North American partner in 2010 for use in North America for otic (ear) infections.
PDF Download

read more »

February 09, 2015

Evolva provides financial and project update

Evolva (SIX: EVE) today provides a financial and project update.According to the provisional, unaudited financials, revenues in 2014 slightly exceeded CHF 10 million (in line with guidance), whilst the year-end cash position of CHF 60.7 million was higher than the CHF 50 million projected in November 2014.
PDF Download - English Version
PDF Download - German Version
 

read more »

January 29, 2015

Aravis sponsors the Wind Risk Management and Mitigation Forum in London on the 4th and 5th of February

Aravis is proud to sponsor the Wind Risk Management and Mitigation Forum taking place in London on the 4th and 5th of February. The conference is organised by Wind Power Monthly, which is widely regarded as the most prestigious magazine in the wind energy sector. In addition, on the second day Aravis will be presenting the topic “Assessing The Impact Of Weather Risk On Cash Flow”. We are excited about the event and are looking forward to meeting you at the conference.

read more »

January 19, 2015

Evolva and Cargill to collaborate on second family of ingredients

Evolva Holding SA (“Evolva”; SIX: EVE) and Cargill have signed an agreement to co-develop a sustainable, customisable, and cost-effective fermentation production process for a second family of high-value food and beverage ingredients.
PDF Download - English Version
PDF Download - German Version

read more »

January 08, 2015

Evolva and L’Oréal reach first milestone in innovative cosmetics ingredient project

Evolva Holding SA (SIX: EVE) today announces the successful completion of the first part of its R&D collaboration with L’Oréal. The parties have agreed to move into the next phase of the multi-year programme.
PDF Download - English Version
PDF Download - German Version

read more »

December 17, 2014

Evolva sells EV-035 Series to Emergent BioSolutions

Evolva Holding SA (“Evolva”, SIX: EVE) today announced that Emergent BioSolutions Inc. (“Emergent”, NYSE: EBS) has acquired Evolva’s anti-bacterial programme, the EV-035 series. The lead compound in the EV-035 series is the broad-spectrum antibiotic GC-072, which is being developed with US government biodefense funding. For Evolva, this transaction is worth up to USD 70.5 million plus royalties.
PDF Download - English Version
PDF Download - German Version

 

read more »

December 11, 2014

Evolva announces multi-product collaboration with Takasago

Evolva Holding SA (SIX: EVE) today announces the signing of a binding term sheet for an exclusive collaboration with Takasago International Corporation, Japan. The aim of the collaboration is to co-develop novel biosynthetic production routes for several undisclosed ingredients with broad applications in the flavours and fragrances industry. Evolva and Takasago will apply Evolva’s fermentation technology platform to develop and optimise yeast strains for the sustainable and cost-effective production of the ingredients.
PDF Download - English Version
PDF Download - German Version

 

read more »

December 08, 2014

Orphan Drug Status Granted to Vesimune for Bladder Cancer

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Vesimune for the treatment of carcinoma in situ (CIS) in the bladder.
PDF Download

read more »

November 18, 2014

Evolva to acquire Allylix

Expands product portfolio and strengthens stevia franchise - Cargill to increase stake in Evolva

Evolva Holding SA (SIX: EVE) has agreed to acquire San Diego-based Allylix, Inc., a privately held yeast fermentation company with a focus on high-value ingredients, in an all-stock transaction. The acquisition will immediately expand Evolva’s product and IP portfolio and enhance the competitiveness of Evolva’s stevia products. Evolva will acquire Allylix in return for an overall consideration of 46 million newly-issued Evolva shares (c. 14.1% of Evolva post transaction). Cargill (Evolva’s partner on its stevia program) will invest USD 4 million in Evolva shares in support of the transaction. The transaction is expected to close by mid-December 2014.
PDF Dowload - English version
PDF Download - German Version
PDF Download - Presentation
 

read more »

November 03, 2014

Evolva's resveratrol shows potential to protect bones during aging

A new study has found that twice-daily resveratrol helps improve key bone health indicators. In a randomised, double-blind, placebo-controlled study published in the Journal of Clinical Endocrinology & Metabolism, Evolva’s trans-resveratrol boosted bone density, bone formation, and resorption in middle-aged men diagnosed with metabolic syndrome – a condition linked to low-grade inflammation that can reduce bone density and lead to osteoporosis. Studies have shown metabolic syndrome affects more than 20% of the adult US population, with prevalence increasing with age.
Download PDF

read more »

September 22, 2014

Telormedix granted European Patent for Vesimune

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and infectious diseases, announced today that it has been granted the European Patent No. 2393474 entitled "Pharmaceutical compositions comprising imidazoquinolin (amines) and derivatives thereof suitable for local administration" by the European Patent Office. The European patent, which will expire in 2030, broadly covers Telormedix’s lead product Vesimune (TMX-101) and its use for the treatment of bladder cancer. Further patents for Telormedix’s Vesimune have also recently been granted in China and Australia.
PDF Download

read more »

September 16, 2014

Marinomed Biotechnologie GmbH: French Nicox S.A. successfully bids for anti-viral eye drop program

Marinomed Biotechnologie GmbH agreed to sell its promising anti-viral eye drop program to Nicox S.A. of France. The France-based international ophthalmic company acquires the entire program as well as all associated rights, data, contracts and information. In return Marinomed will receive up to € 5.3 Mio. The anti-viral eye drop program of Marinomed derives from the successful technology platform Mavirex® which exploits anti-viral effects of polymers from red algae. One of the polymers, Carragelose®, has demonstrated anti-viral activity in preclinical studies, including with three of the most important adenoviruses causing conjunctivitis. The deal provides Nicox with rights and know-how to develop an innovative anti-viral product for managing viral conjunctivitis.
PDF Download - English Version
PDF Download - German Version

read more »

September 12, 2014

Le sérieux candidat à la cotation

SYMETIS. La start-up medtech (Ecublens- Lausanne) a obtenu une seconde accréditation en Europe. Bien positionné pour devenir numéro trois mondial. - Article in L'agefi Suisse, 12th September 2014

Le lausannois Symetis est déjà un conversation piece de l’investissement dans les sciences de la vie depuis un moment et les spéculations devraient nettement s’amplifier. La start-up est vouée à passer
une étape forte. L’annonce publique d’un second marquage CE (accréditation de conformité en Europe) place maintenant la structure en position favorite pour devenir numéro trois mondial dans sa spécialité,
la valve cardiaque implantée par chirurgie mini invasive. Derrière Medtronic et Edwards Lifesciences. La cotation fait partie des hypothèses. Jacques Essinger, président exécutif de Symetis, ne commente pas, l’échéance est entre les mains des actionnaires, mais il n’écarte rien: «L’IPO n’est pas la seule éventualité.» Il évoque aussi la possibilité d’une alliance stratégique ou la reprise par un fonds privé, avec peut-être le projet de créer un opérateur de poids dans le cardio-vasculaire.
PDF Download
 

read more »

September 12, 2014

Symetis receives CE Mark approval for transfemoral transcatheter aortic heart valve system ACURATE neo™, and launches product with first commercial implantations

Symetis joins industry leaders Edwards Lifesciences and Medtronic as only companies to offer both transapical and transfemoral options for transcatheter aortic heart valve delivery

Symetis SA, the leading European developer of transcatheter aortic valve implantation (TAVI) systems, announced today the launch of ACURATE neo™, its 15F compatible transfemoral TAVI system. Commercial implantations started early September after Symetis received CE Mark approval for ACURATE neo this summer.
PDF Download

 


 

read more »

September 02, 2014

Evolva’s first half results show higher revenues and a strong balance sheet

First products on market.

Reinach, Switzerland, 2 September 2014 – Evolva Holding SA (SIX: EVE) today announces its financial results for the period 1 January to 30 June 2014. The condensed half-year accounts are available on Evolva’s website.
PDF Download - English Version
PDF Dowload - German Version
PDF Download - Half Year Report in English
PDF Download - Presentation in English

read more »

August 29, 2014

Biotie: Selincro enters the market in Germany

Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has brought Selincro on the market in Germany. According to the terms of the license agreement between Biotie and Lundbeck for Selincro, Biotie is eligible for a milestone payment of EUR 2 million related to the market entry. Lundbeck will continue the rollout of Selincro in additional European markets during 2014.
PDF Download

read more »

August 15, 2014

Evolva & Cargill Announce Publication Of Stevia Reb M Patent Application

Evolva and Cargill are pioneering the production of great tasting, next-generation sweeteners via fermentation

Evolva Holding SA (SIX:EVE) announced that its patent application (WO 2014122227) on a process to efficiently and sustainably produce next-generation sweeteners via fermentation, including Rebaudioside M (“Reb M”), has now published. The patent application was originally filed on February 6, 2013.
PDF Download - English Version
PDF Dowbload - German Version

read more »

August 04, 2014

Evolva strengthens in-silico capabilities with acquisition of Prosarix

Evolva Holding SA (SIX: EVE) today announces the acquisition of Cambridge, UK based Prosarix Ltd., a leading in silico (computational) modelling company focusing on small molecule identification, design, biosynthesis and function.
PDF Download - English Version
PDF Download - German Version

read more »

July 30, 2014

Biotie updates outlook on tozadenant and SYN120

Tozadenant to advance into Phase 3 in Parkinson's disease within Biotie's proprietary portfolio and SYN120 to advance into Phase 2 in Parkinson's disease dementia, further strengthening Biotie's presence in Parkinson's disease space

Biotie has decided to advance tozadenant, its adenosine A2a receptor antagonist for Parkinson's disease, into Phase 3 development as part of the Company's proprietary portfolio. Preparations for Phase 3 development are ongoing, and it is expected that the Phase 3 clinical studies can commence recruitment in H1 2015, as originally planned.
PDF Download

read more »

July 24, 2014

Clinical study with Biotie's BTT1023 in primary sclerosing cholangitis awarded external grant funding

Biotie Therapies Corp. will be working in partnership with the University of Birmingham, UK, who have been awarded funding of up to approximately EUR 1.0 million for an investigator-sponsored, Phase 2, proof of concept study with its vascular adhesion protein-1 (VAP-1) antibody, BTT1023, in primary sclerosing cholangitis (PSC). PSC is a chronic and progressive orphan fibrotic disease for which there are currently no approved therapeutic treatments. The study will be conducted in the UK and is expected to start recruiting patients by the end of 2014.
PDF Download

read more »

July 22, 2014

Biotie: Selincro enters the market in Spain

Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has brought Selincro on the market in Spain. According to the terms of the license agreement between Biotie and Lundbeck for Selincro, Biotie is eligible for a milestone payment of EUR 2 million related to the market entry. Lundbeck will continue the rollout of Selincro in additional European markets during 2014.
PDF Download

read more »

July 10, 2014

Biotie: Selincro receives positive draft guidance from UK's NICE

Biotie Therapies (Biotie) announces that the National Institute for Health and Care Excellence (NICE), the United Kingdom's health technology assessment authority, has issued draft guidance recommending the use of Selincro (nalmefene) within the conditions of its marketing authorization in the National Health Service (NHS) in England. The draft guidance is open for comments until July 29, and final guidance is expected in November 2014.
PDF Download

read more »

July 08, 2014

Biotie: Tozadenant Phase 2b Parkinson's disease study published in Lancet Neurology

Biotie announces that full data from the positive Phase 2b study evaluating tozadenant, an adenosine A2a antagonist, in Parkinson's disease patients experiencing end of dose wearing off have been published in Lancet Neurology (Hauser RA, Olanow CW, Kieburtz KD, et al. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol 2014; published online July 7. http://dx.doi.org/10.1016/S1474-4422(14)70148-6). The Phase 2b study was an international, randomised, double blind, placebo-controlled, parallel group, dose finding study in 420 levodopa-treated patients with end of dose wearing off (i.e at least 2.5 hours off time per day). Patients received either 60mg, 120mg, 180mg or 240mg tozadenant or matching placebo twice daily for 12 weeks.  The primary outcome was a change from baseline to week 12 in hours per day spent in the off-state, assessed from patient diaries. As previously disclosed, the study demonstrated that tozadenant, when compared to placebo, decreased levodopa related motor fluctuations.
PDF Download

read more »

June 18, 2014

MerLion completes recruitment in Finafloxacin phase II cUTI trial

MerLion Pharmaceuticals (MerLion) announced today that it has completed the planned recruitment into its Phase II trial in patients hospitalized with Complicated Urinary Tract Infection, including pyelonephritis (“cUTI”) in Germany and Poland.
PDF Download

read more »

May 28, 2014

Evolva starts commercial resveratrol production

Evolva Holding SA (SIX: EVE) today announces the start of commercial production of its resveratrol ingredient. Evolva has succeeded in optimising and scaling the fermentation process, resulting in competitive production costs that allow a commercial launch. Evolva’s resveratrol is high-purity (>98% pure trans-Resveratrol), with a controlled and reliable supply chain, produced from natural and sustainable feedstocks. It is the only resveratrol product made by brewing.
PDF Download - English Version
PDF Download - German Version

read more »

May 27, 2014

Biotie: nepicastat study in cocaine dependence completes enrollment ahead of schedule - top-line data expected around end 2014

Biotie Therapies today announced that patient enrollment into the Phase 2 study investigating nepicastat for cocaine dependence has been completed ahead of schedule. The 11-week, 179-patient study is being conducted at 10 US clinics under a Collaborative Research and Development Agreement (CRADA) with the National Institute on Drug Abuse (NIDA) at the US National Institutes of Health. Top-line results from the study are expected around the end of 2014
PDF Download

read more »

May 26, 2014

MerLion Announces a Significant Milestone in the Development of Finafloxacin for Treatment of Acute Otitis Externa

MerLion Pharmaceuticals (MerLion) announced today that its North American partner has achieved a significant regulatory milestone in the development of finafloxacin for the treatment of acute otitis external (bacterial infection of the outer ear).
PDF Download

read more »

May 21, 2014

Evolva achieves key milestone in Stevia project with Cargill

Cargill and Evolva Holding SA (SIX: EVE) today announced the achievement of a technical milestone in their joint development program of fermentation-based minor steviol glycosides - the compounds responsible for the sweet taste in the stevia leaf. The milestone is an enabling step in bringing additional great tasting stevia-based sweeteners to market in a cost effective and sustainable way for food and beverage manufacturers.
PDF Download - English Version
PDF Download - German Version

read more »

May 16, 2014

Telormedix’s Vesimune Successfully Completes Phase II for Carcinoma In Situ of the Bladder

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has successfully completed a Phase II trial, conducted under an IND, of Vesimune (TMX-101) in CIS (carcinoma in situ) of the bladder.
PDF Download

read more »

March 27, 2014

RuiYi Announces $15 Million Series B to Advance Pipeline of Therapeutic Monoclonal Antibodies Targeting GPCR Receptors

Cannabinoid Receptor 1 is most recent GPCR to be targeted by RuiYi’s iCAPS platfrom

RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA. RuiYi has a pipeline of innovative monoclonal antibodies to previously untargeted G protein coupled receptors (GPCRs) for important global, therapeutic needs. The financing will support the continued development of RuiYi's lead asset, RYI-008, a novel anti-IL-6 monoclonal antibody (mAb), and the discovery and development of new therapeutic mAbs targeting GPCRs, including a first-in-class mAb to cannabinoid receptor 1 (CB-1), a commercially validated but previously intractable drug target. In addition, RuiYi expanded the leadership team, appointing Erik Karrer, Ph.D. as chief scientific officer and Brian Campion, Ph.D. as vice president of business development.
PDF Download

read more »

March 21, 2014

Biotie to regain global rights to tozadenant from UCB

• Tozadenant is transitioning into Phase 3 development for Parkinson's disease • Biotie to host a conference call for analysts and media today at 14:00 Central European time

Biotie Therapies Corp. announced today that UCB Pharma S.A. (UCB) will return global rights to tozadenant to Biotie. Tozadenant (SYN115), a selective inhibitor of the adenosine 2a (A2a) receptor, has delivered clinically relevant and statistically highly significant effects in Parkinson's disease, across multiple pre-specified evaluation parameters, in a 420 patient Phase 2b study completed in December 2012. Tozadenant is expected to start recruitment for the Phase 3 program in H1 2015.
PDF Download

read more »

March 12, 2014

Novimmune appoints Andrew J. Oakley as CFO

Novimmune SA announced today that Andrew J. Oakley has joined the company as Chief Financial Officer.
PDF Download

read more »

February 26, 2014

Evolva successfully places new shares

Evolva Holding SA (SIX: EVE, “Evolva” or the “Company”) has successfully completed its placement of shares which was announced yesterday. Evolva has sold 27,000,000 new shares via an accelerated bookbuild process by way of a private placement in Switzerland and outside of Switzerland in accordance with applicable securities laws. The shares have been placed at a price of CHF 1.37 per share, representing a discount of 4.9% to the closing price of 25 February 2014.
PDF Download - English Version
PDF Download - German Version

read more »

February 25, 2014

Evolva reports preliminary, unaudited financial results for 2013 and announces launch of share placement

Evolva Holding SA (SIX: EVE, “Evolva” or the “Company”) today announces its preliminary, unaudited financial results for 2013. In 2013, the Company had total revenues of CHF 8.7 million compared with CHF 7.0 million in 2012 and generated an operational loss of CHF 17.7 million (2012: CHF 20.0 million). The cash outflow from operations and investment amounted to CHF 13.6 million (2012: CHF 14.0 million). At the end of 2013, the Company had CHF 29.3 million in cash and cash equivalents. Each of these parameters is within the guidance provided in August 2013. The audited financial report for 2013 will be released on 8 April 2014, as previously announced.
PDF Download - English Version
PDF Download - German Version
 

read more »